Form 8-K - Current report:
SEC Accession No. 0001628280-22-001252
Filing Date
2022-01-25
Accepted
2022-01-25 17:13:52
Documents
14
Period of Report
2022-01-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20220125.htm   iXBRL 8-K 43041
2 EX-99.1 ex991jan252022.htm EX-99.1 1101
6 image_0a.jpg GRAPHIC 585688
  Complete submission text file 0001628280-22-001252.txt   997675

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20220125.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20220125_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20220125_pre.xml EX-101.PRE 13731
8 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20220125_htm.xml XML 11887
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22554734
SIC: 2836 Biological Products, (No Diagnostic Substances)